The number of prescription drug shortages in the U.S. fell by 23% last year, marking the second consecutive year of declines and the lowest level since 2017, according to a new analysis that otherwise found troubling signs about medicines that are in short supply.
For instance, the average drug shortage lasted 5.3 years, exceeding the 4.3 years seen in 2024 and greatly outpacing the average two-year shortage experienced in 2019. Moreover, nearly two-thirds of out-of-stock medicines were in short supply for more than three years, and 39% were unavailable for more than five years.
Meanwhile, the 75 drugs that were in short supply last year spanned 130 therapeutic categories, indicating that shortages affected a wide range of diseases and patient populations, according to the analysis by U.S. Pharmacopeia, an independent organization that develops standards for medicines.
You know that 1980s Dolly Parton hit “9 to 5”? I wonder if RFK Jr. has heard it? He often works in his office from 10 a.m. to 4 p.m., according to the New York Times. Send news tips and ways to make a livin’ to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.
Hidden alcohol study revealed
The federal government paid for a report on alcohol consumption. But it refused to publish the results, which show that even people who drink less than one alcoholic beverage a day are increasing their chances of developing a serious illness, Isabella Cueto reports.
The scientists who conducted the study believe the findings were suppressed because they are unfavorable to powerful special interests.
The condemnations keep coming four days after security officers escorted five diabetes experts out of the American Diabetes Association meeting in New Orleans for handing out copies of an editorial criticizing federal cuts to biomedical research. Expelling the doctors and scientists has shocked people in the field, and the ADA’s communications explaining it have only made matters worse, leaders in diabetes research and practice told STAT.
Background: Chronic insomnia is a highly prevalent sleep disorder that adversely affects quality of life and mental health. Cognitive behavioral therapy for insomnia (CBT-I) is internationally recommended as the first-line treatment, and digital CBT-I (dCBT-I) has been developed to improve accessibility and scalability. While existing dCBT-I systems effectively support structured behavioral training through standardized protocols, they provide relatively limited support for users’ cognitive exploration and meaning-making processes, particularly in helping users reflect on and internalize the rationale behind CBT-I practices in daily life. These limitations may contribute to challenges in sustained engagement and long-term adherence. Objective: This study aimed to examine the usability and feasibility of SleepPathfinder, a conversational CBT-I support chatbot that integrates Socratic questioning and a self-decision mechanism to support users’ understanding of and engagement with CBT-I practices. Methods: SleepPathfinder was designed around a 4-stage conversational flow: education on CBT-I techniques, Socratic cognitive exploration, self-decision, and advice provision. We conducted (1) a single-session pilot usability study (n=45) to assess system stability and user experience and (2) a 5-day condition-based comparative experiment (n=30) consisting of daily sessions, comparing an exploratory dialogue condition with a directive, protocol-guided dialogue condition. Quantitative measures assessed usability, cognitive appraisals related to sleep problems, autonomy-related experiences, and behavioral readiness, while qualitative feedback and conversational log analyses were used to examine interaction patterns and engagement characteristics. Results: In the comparative experiment, the exploratory dialogue condition showed a tendency toward reduced perceived threat and severity appraisal of sleep problems compared with the directive condition, accompanied by moderate effect sizes in cognitive perception measures. Autonomy-related experiences, including perceived choice and engagement, demonstrated suggestive upward trends in the exploratory condition. Behavioral intention changes were comparable across conditions, while overall readiness for change increased across participants. Conversational log analyses indicated that greater depth and volume of user self-narrative were associated with larger shifts in cognitive appraisals, whereas the frequency of chatbot questions alone was not. The pilot usability study indicated generally positive evaluations of system usability and content credibility, while identifying areas for improvement in emotional responsiveness and conversational naturalness. Conclusions: These findings suggest that a Socratic questioning–based and self-decision–based conversational structure is usable and feasible as a supportive interaction layer within dCBT-I systems. Rather than altering the directive behavioral structure of CBT-I, such an approach may complement existing protocols by facilitating cognitive exploration and supporting user-perceived autonomy. This study provides design-oriented evidence to inform the refinement of dialogue-supported digital CBT-I systems aimed at enhancing user engagement with CBT-I practices.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/53b6f3cffbd734291f43739e09584341" />
WASHINGTON — Federal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years, giving Americans access to a skin-protecting chemical long used in Europe and other parts of the world.
The Food and Drug Administration says the ingredient, bemotrizinol, met the agency’s standards for protecting from dangerous ultraviolet rays while causing little irritation or absorption into the skin. The ingredient is safe for adults and children 6 months and older, the agency stated in a release.
WASHINGTON — The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information — arguing that the lack of disclosure is keeping healthcare costs higher than they should be.
The Associated Press obtained exclusively the list of hospitals that since April have either received letters of warning or, in more severe cases, requests to submit plans to provide transparent pricing. Failing to comply with the warnings comes with penalties as high as $2 million annually for each recipient that doesn’t create a plan to post clear pricing data.
<![CDATA[Phase 2 depression trial shows ALTO-203 boosts attention, EEG theta-beta ratio and alertness, pointing to biomarker-guided dosing and precision psychiatry.]]>
Obsessive-Compulsive Disorder (OCD) is often misunderstood as a condition involving excessive cleanliness, organization, or ritualistic behavior. In reality, OCD is a complex mental health disorder characterized by intrusive thoughts, unwanted images, fears, and compulsive behaviors intended to reduce anxiety. One of the least understood and most painful aspects of OCD occurs when intrusive thoughts intersect with sexuality, creating a profound sense of shame, confusion, and isolation.
Sexuality is already a deeply personal aspect of human identity. Many people grow up receiving messages, whether from family, religion, culture, or society, that certain thoughts, desires, or identities are inappropriate or unacceptable. When OCD enters this landscape, it can weaponize these fears and vulnerabilities. Intrusive thoughts often target what a person values most or fears most. As a result, individuals with OCD may experience unwanted sexual thoughts that feel completely inconsistent with their values, identity, or desires.
Someone with OCD may become trapped in relentless questioning: “What if I am attracted to someone I shouldn’t be attracted to?” “What if these thoughts mean something about who I really am?” “What if I am secretly a bad person?” These questions are not driven by genuine desire but by overwhelming anxiety and uncertainty. Nevertheless, the individual often feels compelled to seek reassurance, analyze their reactions, or avoid situations that trigger distress.
The shame surrounding sexuality intensifies this struggle. Society frequently treats sexual thoughts as reflections of character rather than recognizing that thoughts can occur without intent, desire, or meaning. For people with OCD, this misunderstanding can be devastating. Many become terrified that simply having an intrusive thought makes them immoral, dangerous, or fundamentally flawed. As a result, they often suffer in silence, afraid that disclosing their thoughts will lead to judgment or rejection.
The intersection of OCD and sexuality can affect people of all sexual orientations and gender identities. Some individuals experience obsessions centered on questioning their sexual orientation, regardless of whether they identify as heterosexual, gay, bisexual, or otherwise. Others experience intrusive thoughts involving taboo or unwanted sexual scenarios. In each case, the distress comes not from the thoughts themselves but from the meaning the individual fears those thoughts represent.
This experience is particularly challenging because shame thrives in secrecy. The more a person attempts to suppress, analyze, or eliminate intrusive thoughts, the stronger and more persistent those thoughts often become. OCD feeds on certainty-seeking, convincing individuals that if they can just think hard enough or find enough reassurance, they will finally feel safe. Unfortunately, the cycle rarely ends that way.
Recovery begins when individuals learn to separate intrusive thoughts from identity and intention. Evidence-based treatments such as Exposure and Response Prevention (ERP) help people tolerate uncertainty and reduce compulsive responses. Through treatment, many discover that thoughts are not actions, urges are not intentions, and anxiety is not evidence. They learn that having an intrusive thought says far less about their character than the courage it takes to face that thought without engaging in compulsions.
Understanding the intersectionality of OCD and sexual shame requires compassion, education, and nuance. It demands that we challenge cultural assumptions about thoughts and morality while recognizing the unique suffering OCD can create. When people understand that intrusive thoughts are a symptom of a disorder rather than a reflection of character, shame begins to lose its power.
Ultimately, healing occurs not when every intrusive thought disappears, but when individuals no longer measure their worth by the thoughts that enter their minds. By replacing shame with understanding and fear with self-compassion, people living with OCD can reclaim both their mental health and their sense of identity.
<![CDATA[Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.]]>
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
The outspoken longevity scientist David Sinclair has predicted that, one day, you’ll go to the doctor and get a prescription that will make you 10 years younger. MIT Technology Review has learned of his latest step toward this: human tests of a “reprogramming” drug.
Sinclair, a biologist at Harvard Medical School, plans to launch the tests in a $101 million competition organized by the XPrize Foundation. The winners will “restore” a person to an earlier apparent age, as measured by improvements in immune, cognitive, and muscle function.
The grand prize goes to any team able to show a 10-year (or greater) relative improvement after one year of treatment.
At SXSW London last week, I gave a talk called “Five things you need to know about AI,” in which I shared what I think are the biggest themes in AI right now.
I pulled a few things from our first AI10 list, an annual guide to the top trends in this buzzy world, but I also veered off on several tangents. In my half-hour slot, I tried to cover the key talking points that I think help to make sense of what’s going on in tech—and thus the economy—today.
Five key thoughts emerged: AI is everywhere all at once, it’s getting scary, a backlash is growing, it’s becoming a big deal for science—and I didn’t even need to show up at the talk. Read the full story for all the details.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 OpenAI has confidentially filed for a US IPO The listing could come as early as September. (Reuters $) + OpenAI is targeting a valuation of up to $1 trillion. (Financial Times $) + The IPO will test investor appetite for AI companies. (WSJ $) + The move follows IPO filings from Anthropic and SpaceX. (CNN)
2 The US claims BYD, Baidu, Alibaba, and others are aiding China’s military The Pentagon added them to a list of military-linked companies. (WSJ $) + The designations limit their operations in the US. (BBC) + The new additions also include humanoid firm Unitree. (TechCrunch) + The Pentagon is adapting to China’s tech rise. (MIT Technology Review)
3 Apple’s long-awaited AI overhaul of Siri is finally here “Siri AI” promises to be a more conversational assistant. (NYT $) + It includes a standalone app and screen-reading features. (Reuters $) + And arrives after two years of repeated delays. (Axios)
4 The White House and Congress are working to limit state AI laws A new deal would curb state rules for federal legislation. (Axios) + AI regulation has divided US politicians. (MIT Technology Review)
5 Meta is launching a “workforce academy” for building data centers The five-week program is free of charge and guarantees a job. (WSJ $) + It arrives shortly after Meta laid off 8,000 employees. (NPR) 6 Taiwan is mulling curbs on AI chip exports to China The new controls would further align with US restrictions. (Bloomberg $) + Future AI chips could be built on glass. (MIT Technology Review)
7 Meta has quietly removed face-recognition code from its smart glasses app The code identified by investigators has disappeared. (Wired $)
8 Humanoid robots are edging towards the battlefield American and Chinese militaries are pursuing the tech. (BBC)
9 The world’s first wind-powered underwater data center has launched It uses less power and water than land-based equivalents. (Guardian)
10 You could get some benefits of sleep without having to nod off If new brain stimulation works as well on humans as on mice, that is. (New Scientist $)
Quote of the day
“You’re on the train, but you know that there’s no destination.”
—Clara Shih, a former top AI executive at Salesforce and Meta, tells the New York Times that AI training can’t keep up with the field’s advances.
One More Thing
ILLUSTRATIONS BY AMRITA MARINO
Inside the race to make human sex cells in the lab
An embryo forms when sperm meets egg. But what if we could start with other cells—if a blood sample or skin biopsy could be transformed into “artificial” sperm and eggs? What if those were all you needed to make a baby?
That’s the promise of a radical approach to reproduction. Scientists have already created artificial eggs and sperm from mouse cells and used them to create mouse pups. Artificial human sex cells are next.
The advances could herald the end of infertility, but they raise major scientific and ethical challenges.
